The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 13, 2026
Snapshot (as of Jul 13, 2026): Gilead Sciences, Inc. (GILD) pays a $3.22 annual dividend ($0.82 quarterly), yielding 2.45% at $131.40/share. Next ex-dividend date 2026-06-15. 9+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.45%
Annual Dividend: $3.22 per share
Payout Ratio: 43.8%
Ex-Dividend Date: 2026-06-15
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 12
Gilead Sciences, Inc. dividend income comes from one of the largest biopharmaceutical companies in the world, built on HIV therapies like Biktarvy and Genvoya, cancer treatments, and antiviral drugs including Veklury. GILD currently yields 2.52%, with a trailing annual dividend rate of $3.22 per share paid quarterly. The next ex-dividend date is June 15, 2026. A beta of 0.331 means GILD stock moves far less than the broader market, which suits income investors who prioritize low volatility over aggressive price appreciation.
Gilead Sciences, Inc. pays out 43.8% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful room to absorb earnings pressure without threatening the dividend, and GILD's portfolio of HIV treatments, which includes market-leading therapies like Biktarvy, addresses chronic conditions requiring long-term medication. The primary risk to Gilead Sciences, Inc. dividend safety is pipeline and patent dependency: if key products face generic competition or clinical setbacks, earnings could compress and pull the payout ratio higher.
Over the past nine years, Gilead Sciences, Inc. dividend history shows a CAGR of 6.2% per year from 2016 to 2025. Per-share payments grew from $1.84 to $3.16 over that window (2026 is a partial year and excluded from the CAGR). The smallest annual increase in the window was 2.6% in 2025, a meaningful step down from the 13.0% peak increase recorded in 2017.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +2.7% | $2.92 (2022) | $3.16 (2025) |
| 5-Year | +3.0% | $2.72 (2020) | $3.16 (2025) |
| 10-Year | +9.4% | $1.29 (2015) | $3.16 (2025) |
GILD fits dividend investors who want a moderate yield backed by a large-cap biopharmaceutical business with a low-volatility profile. The current yield of 2.52% sits in the moderate (2-4%) range, slightly above the five-year average of 2.35%, which means income buyers are getting a marginally better entry point on yield than the historical norm. Nine consecutive years of increases and a 43.8% payout ratio give the dividend room to keep growing. The trade-off is growth pace: at 6.2% annually over the full window, and just 2.6% in 2025, the dividend is growing but not accelerating. Income investors gain a low-beta stock with a durable payout; they accept modest yield and slowing growth in return.
| Payment Date | Amount per Share |
|---|---|
| 2026-06-15 | $0.8200 |
| 2026-03-13 | $0.8200 |
| 2025-12-15 | $0.7900 |
| 2025-09-15 | $0.7900 |
| 2025-06-13 | $0.7900 |
| 2025-03-14 | $0.7900 |
| 2024-12-13 | $0.7700 |
| 2024-09-13 | $0.7700 |
| 2024-06-14 | $0.7700 |
| 2024-03-14 | $0.7700 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.6400 |
| 2025 | $3.1600 |
| 2024 | $3.0800 |
| 2023 | $3.0000 |
| 2022 | $2.9200 |
Project income from GILD with the GILD dividend calculator or track your full portfolio with the dividend tracker.